- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Scott Lassman: Changes to the FDA Under Scott Gottlieb, MD
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes how the FDA has changed under its current leadership.
Transcript:
Can you comment on how the FDA has changed under new leadership by Commissioner Scott Gottlieb, MD?
The FDA is like a big freighter ship: it doesn’t change really quickly. That being said, I actually have seen a number of changes, or what I perceive to be changes, which is that he’s not shying away from some of the most controversial issues. I thought it was telling that Dr. Gottlieb jumped right in and said that FDA has a role in drug pricing. This was something that the FDA has shied away from for years. While Dr. Gottlieb was clear that the FDA does not have a direct role, he did say they have an indirect role, and is trying to take action to actually speed up the approval of generic drugs and biosimilars. I think he actually has been doing that, if you look at some of the recent approvals for very complex generic products (almost, one would say biosimilar-like), that had been sitting at the FDA for a long time, they’re taking action to actually move those products forward and get them in the market. He seems to be—what I would say is the big issue—he’s not shying away from the controversial issues. He’s stepping right in, and they seem to be taking a lot bolder action and taking it a lot more quickly than I would have expected.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
